Pretomanid-resistant tuberculosis.

Competing Interests: Declaration of Competing Interest C.K. received personal fees from INFECTOPHARM outside the scope of this work; C.K. received speakers honoraria from GILEAD and SHIONOGI outside the scope of this work; B.K. received personal fees from INSMED outside the scope of this work; S.N. received grants from German Center for Infection Research, Excellence Cluster Precision Medicine in Chronic Inflammation EXC 2167, and Leibniz Science Campus Evolutionary Medicine of the LUNG (EvoLUNG), during the conduct of the study; S.N. received consultation fees from ILLUMINA outside the scope of this work; C.L. received consulting fees from INSMED outside the scope of this work; C.L. received speakers honoraria from INSMED, GILEAD, and JANSSEN outside the scope of this work; C.L. is a participant on Data Safety Boards of Medicines sans Frontiers outside the scope of this work; all other authors have nothing to disclose.